Evidence map›Paper›PMID 28903507›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2017

CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC).

Adam Trickey, Margaret T May, Philipp Schommers, Jan Tate, Suzanne M Ingle, Jodie L Guest, M John Gill, Robert Zangerle, Mike Saag, Peter Reiss and 9 more

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Persistent CD8Frontiers in immunology · 2026
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Adam TrickeySchool of Social and Community Medicine, University of Bristol, United Kingdom.
Margaret T MaySchool of Social and Community Medicine, University of Bristol, United Kingdom.
Philipp SchommersDepartment I for Internal Medicine, University Hospital of Cologne, Germany.
Jan TateYale University School of Medicine, West Haven, Connecticut.
Suzanne M IngleSchool of Social and Community Medicine, University of Bristol, United Kingdom.
Jodie L GuestHIV Atlanta Veterans Affairs Cohort Study, Atlanta Veterans Affairs Medical Center, Decatur, Georgia.
M John GillDivision of Infectious Diseases, University of Calgary, Alberta, Canada.
Robert ZangerleInnsbruck Medical University, Austria.
Mike SaagDivision of Infectious Disease, Department of Medicine, University of Alabama, Birmingham.
Peter ReissStichting HIV Monitoring, and Division of Infectious Diseases and Department of Global Health, Academic Medical Center, University of Amsterdam, and Amsterdam Institute for Global Health and Development, The Netherlands.
Antonella d'Arminio MonforteClinic of Infectious Diseases and Tropical Medicine, San Paolo Hospital, University of Milan, Italy.
Margaret JohnsonDepartment of HIV Medicine, Royal Free London NHS Foundation Trust, United Kingdom.
Viviane D LimaBritish Columbia Centre for Excellence in HIV/AIDS, and Division of AIDS, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
Tim R SterlingVanderbilt University School of Medicine, Nashville, Tennessee.
Matthias CavassiniService of Infectious Diseases, Lausanne University Hospital and University of Lausanne, Switzerland.
Linda WittkopINSERM, Unit of Epidemiology and Biostatistics, Bordeaux.
Dominique CostagliolaSorbonne Universités, INSERM, UPMC Université Paris 06, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France.
Jonathan A C SterneSchool of Social and Community Medicine, University of Bristol, United Kingdom.
Antiretroviral Therapy Cohort Collaboration (ART-CC)

Funding

Tennessee CFAR: Implementation of Culturally Responsive Trauma-Informed Care with Youth with HIV in Memphis, TNP30AI110527 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI John Koethe · 2015 to 2026
$27.5M
Alcohol Associated Outcomes Among HIV+/- Aging VeteransU10AA013566 · NIAAA · YALE UNIVERSITY · PI JUSTICE, AMY CAROLINE · 2006 to 2010
$12.7M
Sex Disparities in Overall Response to ART Among HIV Infected IndividualsU24AA020794 · NIAAA · YALE UNIVERSITY · PI JUSTICE, AMY CAROLINE · 2011 to 2020
$5.5M
Medical Research Council G0100221Medical Research Council G0700820Medical Research Council MR/J002380/1NIAAA NIH HHS U10 AA013566NIAAA NIH HHS U24 AA020794NIAID NIH HHS P30 AI110527
6 · The paper itself

Abstract

backgroundWe investigated whether CD4:CD8 ratio and CD8 count were prognostic for all-cause, AIDS, and non-AIDS mortality in virologically suppressed patients with high CD4 count.

methodsWe used data from 13 European and North American cohorts of human immunodeficiency virus-infected, antiretroviral therapy (ART)-naive adults who started ART during 1996-2010, who were followed from the date they had CD4 count ≥350 cells/μL and were virologically suppressed (baseline). We used stratified Cox models to estimate unadjusted and adjusted (for sex, people who inject drugs, ART initiation year, and baseline age, CD4 count, AIDS, duration of ART) all-cause and cause-specific mortality hazard ratios for tertiles of CD4:CD8 ratio (0-0.40, 0.41-0.64 [reference], >0.64) and CD8 count (0-760, 761-1138 [reference], >1138 cells/μL) and examined the shape of associations using cubic splines.

resultsDuring 276526 person-years, 1834 of 49865 patients died (249 AIDS-related; 1076 non-AIDS-defining; 509 unknown/unclassifiable deaths). There was little evidence that CD4:CD8 ratio was prognostic for all-cause mortality after adjustment for other factors: the adjusted hazard ratio (aHR) for lower vs middle tertile was 1.11 (95% confidence interval [CI], 1.00-1.25). The association of CD8 count with all-cause mortality was U-shaped: aHR for higher vs middle tertile was 1.13 (95% CI, 1.01-1.26). AIDS-related mortality declined with increasing CD4:CD8 ratio and decreasing CD8 count. There was little evidence that CD4:CD8 ratio or CD8 count was prognostic for non-AIDS mortality.

conclusionsIn this large cohort collaboration, the magnitude of adjusted associations of CD4:CD8 ratio or CD8 count with mortality was too small for them to be useful as independent prognostic markers in virally suppressed patients on ART.

Indexed as

CD4-CD8 RatioCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesAdolescentAdultAgedAnti-HIV AgentsBiomarkersCause of DeathEuropeFemaleHIV InfectionsHumansLymphocyte CountMaleMiddle AgedAnti-HIV AgentsBiomarkersantiretroviral therapyCD4:CD8 ratioCD8 countHIVmortality

Identifiers

PMID28903507
PMCPMC5850630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.